User profiles for C. Marosi
 | Christine MarosiProfessor Onkologie Medizinische Universität Wien Verified email at meduniwien.ac.at Cited by 53108 |
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
The European Association for Neuro-Oncology guideline provides recommendations for the
clinical care of adult patients with astrocytic and oligodendroglial gliomas, including …
clinical care of adult patients with astrocytic and oligodendroglial gliomas, including …
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)
The management of patients with brain metastases has become a major issue due to the
increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014, …
increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014, …
Meningioma
… tumours occur most frequently in females in their fifth to seventh decades of life, express
progesterone and oestrogen receptors on their cell membranes, frequently overexpress the c-…
progesterone and oestrogen receptors on their cell membranes, frequently overexpress the c-…
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year …
…, P Hau, AA Brandes, J Gijtenbeek, C Marosi… - The lancet …, 2009 - thelancet.com
Background In 2004, a randomised phase III trial by the European Organisation for Research
and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials …
and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials …
[HTML][HTML] Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
…, K Belanger, AA Brandes, C Marosi… - New England journal …, 2005 - Mass Medical Soc
Background Glioblastoma, the most common primary brain tumor in adults, is usually rapidly
fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to …
fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to …
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 …
Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion
mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet …
mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet …
Prediction of venous thromboembolism in cancer patients
The risk of venous thromboembolism (VTE) is increased in cancer patients. To improve
prediction of VTE in cancer patients, we performed a prospective and observational cohort study …
prediction of VTE in cancer patients, we performed a prospective and observational cohort study …
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised …
A Malmström, BH Grønberg, C Marosi, R Stupp… - The lancet …, 2012 - thelancet.com
Background Most patients with glioblastoma are older than 60 years, but treatment guidelines
are based on trials in patients aged only up to 70 years. We did a randomised trial to …
are based on trials in patients aged only up to 70 years. We did a randomised trial to …
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Background Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its
ligand (PD-L1) showed activity in several cancer types. Methods We performed …
ligand (PD-L1) showed activity in several cancer types. Methods We performed …
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
…, J Bravo-Marques, PM Clement, C Marosi… - The Lancet …, 2016 - thelancet.com
Background Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting
molecular heterogeneity of the disease. We compared two different, single-modality treatment …
molecular heterogeneity of the disease. We compared two different, single-modality treatment …
